You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Cost recovery implementation statement: Good manufacturing practice, From 1 July 2015
Version 1.0, July 2015
This CRIS provides information on how the Therapeutic Goods Administration (TGA) implements cost recovery of activities associated with the manufacture of medicines. TGA regulates manufacturers through application of Good Manufacturing Practice (GMP) principles. This CRIS also reports financial and non-financial performance information and contains financial forecasts for 2015-16. The TGA will maintain the CRIS until the activity or cost recovery for the activity has been discontinued.